3SBio (01530.HK) +0.060 (+0.237%) Short selling $365.07M; Ratio 86.993% announced its 2025 annual results, reporting revenue of RMB17.696 billion, up 94.3% year-on-year, primarily due to licensing revenue from a breakthrough PD-1/VEGF bispecific antibody 707 licensing deal with Pfizer. The company recorded a net profit of RMB8.482 billion, a growth of 305.8%, with an EPS of RMB3.51. The final dividend is maintained at HKD0.25.
AASTOCKS Financial News